Labat AfricaJSE:LAB Equity-to-Asset is 0.25 as of Nov. 2025, which is 4% below its 10-year median of 0.26. The stock has 5 warning signs investors should review. Among 1,008 Drug Manufacturers companies, Labat Africa ranks worse than 86.31% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Labat Africa's Total Stockholders Equity for the quarter that ended in Nov. 2025 was R190.4 Mil. Labat Africa's Total Assets for the quarter that ended in Nov. 2025 was R769.8 Mil.
Therefore, Labat Africa's Equity to Asset Ratio for the quarter that ended in Nov. 2025 was 0.25.
The historical rank and industry rank for Labat Africa's Equity-to-Asset or its related term are showing as below:
JSE:LAB'
s Equity-to-Asset Range Over the Past 10 Years
Min: -0.19 Med: 0.26 Max: 0.41
Current: 0.25
During the past 13 years, the highest Equity to Asset Ratio of Labat Africa was 0.41. The lowest was -0.19. And the median was 0.26.
JSE:LAB's Equity-to-Asset is ranked worse than 86.31% of 1008
companies
in the Drug Manufacturers industry
Industry Median: 0.61
vs JSE:LAB: 0.25
Labat Africa (JSE:LAB) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Labat Africa Equity-to-Asset Related Terms
Labat Africa Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Labat Africa's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
JSE:LAB vs ZTS, UTHR, VTRS: Equity-to-Asset Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Labat Africa's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labat Africa Equity-to-Asset vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Labat Africa's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Labat Africa's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Labat Africa's Equity to Asset Ratio for the fiscal year that ended in May. 2024 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labat Africa (JSE:LAB) has a Equity-to-Asset of 0.25 as of Nov. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Labat Africa and its competitors. This is near median its historical median of 0.26. According to the industry distribution chart, Labat Africa ranks #870 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 86.3%.
Is Labat Africa's Equity-to-Asset too high?
Labat Africa's current Equity-to-Asset of 0.25 is near median its 10-year median of 0.26. The Drug Manufacturers industry median Equity-to-Asset is 0.61. Labat Africa's value of 0.25 is 59% below this industry median. Based on the distribution chart, Labat Africa ranks #870 out of 1008 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Labat Africa's Equity-to-Asset compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Labat Africa ranks #870 out of 1008 companies for Equity-to-Asset. This places Labat Africa in the lower half of its industry. The industry median Equity-to-Asset is 0.61. Labat Africa's value of 0.25 is 59% below this benchmark. While the company's 10-year median is 0.26 vs. the industry median of 0.61, Labat Africa has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Drug Manufacturers company?
The median Equity-to-Asset among Drug Manufacturers companies is 0.61, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labat Africa's current Equity-to-Asset of 0.25 is 59% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Labat Africa and its competitors. For the Drug Manufacturers industry, the median Equity-to-Asset is 0.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labat Africa's current Equity-to-Asset is 0.25, which is near median its own 10-year median of 0.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labat Africa stock overvalued right now?
Based on GuruFocus' analysis, Labat Africa (JSE:LAB) is currently considered Possible Value Trap. The stock's GF Value™ is R0.18, compared to a current price of R0.03 — trading 83.3% below its estimated fair value. The current Equity-to-Asset is 0.25, which is near median its 10-year median of 0.26 and 59% below the Drug Manufacturers industry median of 0.61. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Labat Africa (JSE:LAB), the current Equity-to-Asset is 0.25 as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Labat Africa Ltd is an investment holding company. Through its subsidiaries, the company operates in the following segments; Technology, Head office, and Healthcare. The Technology segment manufactures and distributes integrated circuits South African Micro - Electronic Systems. Head office operations provide management services, logistics and seeks further investment opportunities for the Group. The Healthcare segment generates maximum revenue for the company and focusses on medical cannabis industry in South Africa. Geographically, the company carries out its business operations in South Africa.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
JSE:LAB has been successfully added to your 